BioSpace News Archive

Cyclacel Pharmaceuticals, Inc. announced the pricing of a public offering with expected total gross proceeds of approximately $20 million, before deducting placement agent fees and other offering expenses payable by the Company.

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02)

Two Israeli hospitals deploy Tamar’s non-invasive ventilation (NIV) hood, The Greenhouse, which is available for Hospital Systems and Staff around the world

At the CMA, we are thrilled to see the CMA Foundation make this historic donation to address some of the urgent needs identified by the medical community.

Support is Available for Eligible U.S. Patients Who Have Lost Their Jobs and Health Insurance Coverage Due to the Pandemic

AT-007 demonstrated rapid and sustained reduction in toxic galactitol levels with no accompanying increase in galactose Positive trend on MRI outcomes, including indirect measures of edema, neuronal health and brain galactitol levels in AT-007-treated patients 40 mg/kg dose of AT-007 was well-tolerated with no drug-related adverse events reported in healthy volunteers; evaluation of 40 mg/kg dose in Galactosemia patients remains ongoing NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- Appl

VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels (NIS) (approximately $0.9 million) by the Israel Innovation Authority (IIA). The IIA has approved a budget of approximately $1.8 million for the VB-111 project during 2020, with 50% of this amount as an IIA grant. The funds will support the continued development of VBL’s lead product candidate, VB-111, a fi

Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin ® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, today announced that the company will present data from its first in human study of PEN-866 at the 2020 American Association for Cancer Resear

Proven executive with clinical operations expertise to guide Company’s clinical programs with gene therapies

Inspire Medical Systems, Inc. announced that the U.S. Food and Drug Administration has approved an expanded age range for Inspire therapy to include 18-21 year old patients, as compared to the previous minimum age requirement for patients to be 22 years old.